Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

ovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-GCGRRx and ISIS-GCCRRx for the treatment of type 2 diabetes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other document
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... SPEX ) announced today that it has signed letters ... pharmaceutical ingredients,to supply a portion of the D-tagatose used ... sugar as a treatment for Type 2 diabetes. Inalco ... D- tagatose for the Spherix New Drug Application (NDA) ...
... today announced that it submitted a supplemental New ... Administration (FDA) for approval of a new,indication for ... of patients with Chronic Obstructive,Pulmonary Disease (COPD). SYMBICORT ... asthma in patients 12 years and older., ...
Cached Medicine Technology:Spherix D-tagatose to be Supplied by Inalco SpA 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
(Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers how this software allows businesses to track product movement from beginning to end. ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Haryana government claimed Monday that there was a minor improvement in ... the lowest figure in the country., ,Latest reports suggested that ... now at 822 females per thousand males, director general of health ... had recorded an abysmally low ratio of 819, which placed it ...
... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
... Science is usually viewed with awe, not to mention a little ... people cannot understand, let alone hope to enter. Such an // ... the use of science., ,If the public is to have ... it should fist have a clear sense of what science can ...
... second largest number of HIV/AIDS afflicted people in the world ... of India are very real according to a World Economic ... businesses expect an effect on the business due to AIDS ... surveyed recently and 46 per cent report some ...
... The Office of Fair Trading is responsible for checking ... //manufacturers sell to the NHS. They have to monitor ... the prices should be reasonable. ,The Pharmaceutical ... monitors and legislates the agreement of the pricing and ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2
... Test, v1.5, an FDA-approved HIV-1 RNA assay, is ... used in the regulatory approval for HIV-1 therapies, ... 10 clinical laboratories worldwide. , The ... vitro nucleic acid amplification test for the quantification ...
... ADVANCE Rapid HIV-1/2 Antibody ... qualitative immunoassay to detect ... Virus Type 1 (HIV-1) ... in oral fluid, fingerstick ...
... CHS System takes the time proven technology ... ,The VHS® Supracondylar Cable Plate is designed ... femur fractures including periprosthetic fractures. The combination ... angle of the barrel and the plate ...
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: